Document is current
Any future updates will be listed below
-
Authors
Rade, Michael http://orcid.org/0000-0001-6247-9289
Grieb, Nora
Weiss, Ronald
Sia, Jaren
Fischer, Luise
Born, Patrick
Boldt, Andreas
Fricke, Stephan
Franz, Paul
Scolnick, Jonathan
Venkatraman, Lakshmi
Xu, Stacy
Kloetzer, Christina
Heyn, Simone
Kubasch, Anne Sophie
Baber, Ronny
Wang, Song Yau http://orcid.org/0000-0001-5433-8750
Bach, Enrica
Hoffmann, Sandra
Ussmann, Jule
Schetschorke, Birthe
Hell, Saskia
Schwind, Sebastian http://orcid.org/0000-0002-1315-2332
Metzeler, Klaus H.
Herling, Marco
Jentzsch, Madlen
Franke, Georg-Nikolaus http://orcid.org/0000-0001-8239-002X
Sack, Ulrich
Köhl, Ulrike
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Reiche, Kristin http://orcid.org/0000-0002-4452-4872
Vucinic, Vladan
Merz, Maximilian http://orcid.org/0000-0002-2805-5973
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SPP microbone)
- License Information
-
More Information
Article History
Received: 24 February 2023
Accepted: 26 March 2024
First Online: 19 April 2024
Competing interests
: S.F.: consultant and/or speaker fees from Novartis Pharma, Janssen-Cilag, Vertex Pharmaceuticals (Germany), Kite/Gilead Sciences, MSGO and Bristol-Myers Squibb. U.K.: consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma and Bristol-Myers Squibb. M.M.: advisory boards/honoraria/research support from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks and Takeda. K.H.M.: BMS (consultancy and honoraria), AbbVie (honoraria, research funding), Pfizer (honoraria), Otsuka (honoraria), Janssen (honoraria) and Novartis (consultancy). U.P.: Syros (consultancy, honoraria, research funding), MDS Foundation (membership on an entity’s Board of Directors or advisory committees), Silence Therapeutics (consultancy, honoraria, research funding), Celgene (honoraria), Takeda (consultancy, honoraria, research funding), Fibrogen (research funding), Servier (consultancy, honoraria, research funding), Roche (research funding), Merck (research funding), Amgen (consultancy, research funding), Novartis (consultancy, honoraria, research funding), AbbVie (consultancy), Curis (consultancy, research funding), Janssen Biotech (consultancy, research funding), Jazz (consultancy, honoraria, research funding), BeiGene (research funding), Geron (consultancy, research funding) and Bristol-Myers Squibb (consultancy, honoraria, membership on an entity’s Board of Directors or advisory committees, other, travel support, medical writing support, research funding). M.J.: Novartis (honoraria), Amgen (honoraria), Pfizer (honoraria), Blueprint Medicine (honoraria), BMS (honoraria) and Jazz (honoraria). The remaining authors declare no competing interests.
